ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer

Wang, Zhen; Wei, Lingyun; Li, Jing; Zhou, Han; Li, Si; Chen, Dongsheng; Yu, Yangyang; Zhao, Lele; Zhu, Xixu*; Song, Yong*南方医科大学; 南京大学; 1; y
Translational Lung Cancer Research2021-12DOI: 10.21037/tlcr-21-682
14被引5阅读
引用收藏
分享

摘要

Background: Immunotherapy has brought substantial benefit for patients with advanced non-small cell lung cancer (NSCLC); however, resistance may occur, of which oligoprogression is most common. There are no standard strategies to overcome acquired resistance, thus exploring potential effective approaches is critical. Our study evaluated the clinical outcome of combing stereotactic body radiotherapy (SBRT) with checkpoint inhibitors (CPIs) in oligoprogressive NSCLC. Methods: We retrospectively reviewed patients with advanced NSCLC who received SBRT for oligoprogressive lesions after acquired resistance to CPIs in our hospital between January 2015 and January 2021. Acquired resistance was defined as initial complete/partial response (CR/PR) followed by progression/ death. Oligo patterns of acquired resistance were defined as progression in <= 2 sites of disease. We evaluated the local control rate (LR), progression-free survival (PFS-PO), overall survival (OS-PO), and safety of combing SBRT after oligoprogression. Results: Among 177 patients reviewed, 24 patients were included. Fifteen (62.5%) were diagnosed with adenocarcinoma, and 20 (83.3%) were with stage IV. Before oligoprogression, immunotherapy was used as first-line treatment in 16 (66.7%) patients, and 4 (16.7%) received monotherapy. After combing SBRT with CPIs, the median PFS-PO and OS-PO were 11 months (95% CI: 8-NA) and 34 months (95% CI: 19-NA). The median LC of 34 oligoprogressed lesions was 43 months (95% CI: 7.7-78.3). The 1- and 2-year LC rates were 100% and 81.8%, respectively. Patients with adenocarcinoma, lung immune prognostic index (LIPI) (>= 1), and positive PD-L1 tended to achieve favorable survival benefits. Conclusions: We observed considerable benefit of local control and survival by combing SBRT in patients with oligoprogression after required resistance to CPIs in NSCLC. The adverse events are well managed. Our results suggest that combing SBRT with CPIs could be a potential strategy to overcome acquired resistance.

学科与关键词

关键词
Non-small cell lung cancer (NSCLC)checkpoint Inhibitor (CPI)oligoprogressionstereotactic body radiotherapy (SBRT)survival
相关
加载中…
  • combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer (vol 10, pg 4368, 2021)
    Wang, Zhen*; Wei, Lingyun; Li, Jing; Zhou, Han; Li, Si; Chen, Dongsheng; Yu, Yangyang; Zhao, Lele; Zhu, Xixu; Song, YongTranslational Lung Cancer Research, 2022, 504-505.
  • Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer
    Li, Wen-Cai; Wang, Zhen; Gao, Jie; Zhou, Han; Li, Jing; Zhu, Xi-Xu*Cancer Management and Research, 2021, 13: 1887-1896.被引 4
  • Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
    Chen, Zi-Ying; Duan, Xiao-Tong; Qiao, Si-Miao; Zhu, Xiao-Xia*Cancer Medicine, 2023, 12(2): 995-1006.
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2021-12
卷期
第 10 卷, 第 12 期
页码
4368-+
DOI
10.21037/tlcr-21-682
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Foundation of Nanjing City [SZDZK2016012]

作者

  • W

    Wang, Zhen (第一作者)

    southern med univ

  • W

    Wei, Lingyun

    nanjing univ

查看全部 10 位作者收起作者
  • L

    Li, Jing

  • Z

    Zhou, Han

  • L

    Li, Si

  • C

    Chen, Dongsheng

  • Y

    Yu, Yangyang

  • Z

    Zhao, Lele

  • Z

    Zhu, Xixu (通讯)

  • S

    Song, Yong (通讯)

    southern med univ · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417